Checkpoint Therapeutics

Checkpoint Therapeutics is committed to advancing the development of cancer immunotherapies and targeted oncology treatments, creating accessible, effective, and more affordable options for patients worldwide. Alongside our leading drug candidates, cosibelimab and olafertinib, we are dedicated to accelerating the development and market introduction of cancer therapies. We actively pursue opportunities for product acquisition, licensing, and co-development that align with our expertise, aiming to deliver better patient outcomes and provide significant value to the future of healthcare.